Clinical Vignette {#Sec1}
=================

Today, a very common clinical scenario is a 17-year-old female with a family history of type 2 diabetes mellitus (T2DM) and hypertension in her mother and two first-degree relatives. Three years ago she was diagnosed with polycystic ovarian syndrome (PCOS). She is overweight with her body weight increasing 10 kg in the last 2 years. Additionally, she has acanthosis nigricans (AN) in the axillae and knuckles. Blood tests were unremarkable with a fasting plasma glucose value of 82 mg/dl and an HbA1c of 5.0%.

The first question of this clinical vignette is: does this young woman have T2DM? The answer is, of course, no. The second question is: does she have insulin resistance (IR) with compensatory hyperinsulinemia? The answer is yes. Currently, however, the approach endorses a delay of one to two decades to establish a diagnosis of T2DM. Based on this everyday clinical case and the predictable medical actions recommended for the patient, the next question is: do we really understand which is the initial true time to act against T2DM? Should it be with clinical expression of IR or hyperglycemia?

Introduction {#Sec2}
============

Previous projections of T2DM prevalence have been exceeded, with a current worldwide prevalence of more than 435 million patients \[[@CR1]\]. The socioeconomic implications of this epidemic threaten worldwide public health systems, and epidemiologic statistics of T2DM/obesity are familiar to all clinicians. In fact, there has been a 100 million increment in T2DM cases in the last 10 years and an annual death rate of 1.5 million \[[@CR2]\]. Three out of four patients with T2DM are economically active and more than 30% of the global economic burden estimated for T2DM is due to indirect expenses with mortality as the main associated cause \[[@CR3]\]. The current projections are of catastrophic socioeconomic consequences and require an immediate call for action. The T2DM epidemic requires a different medical approach. Efforts to prevent major macrovascular complications and reduce their mortality have been ineffective \[[@CR4]\]. Antidiabetic medications that have shown evidence of macrovascular risk reduction have been studied only in very high-risk cardiovascular patients with T2DM, and, unfortunately, these drugs are not easily available for many patients, particularly in countries with a very high incidence of T2DM, such as in developing countries \[[@CR5]\]. As a consequence, the main emphasis must focus on very early prevention of T2DM and cardiovascular disease (CVD). This strategy, however, must be centered not on the development of hyperglycemia but on the disorders occurring as a result of earlier pathophysiological mechanisms, such as IR. Its manifestations are tissue-specific signs that arise as the metabolic burden worsens, some even before the development of weight gain or obesity \[[@CR6]--[@CR10]\]. Despite the absence of consensus in the diagnosis and management of IR, there is no question that T2DM, hypertension, obesity, non-alcoholic fatty liver disease (NAFLD), androgenetic alopecia, and AN are well-recognized clinical expressions of IR, particularly when they occur as a cluster and are associated with a family history of the same.

This article is based on previously conducted studies and does not involve any new studies of human or animal subjects performed by any of the authors.

Early Clinical Expressions of Insulin Resistance {#Sec3}
================================================

AN, classically described in the neck, axillae, and elbows of patients with obesity, has been recently reported as an early and straightforward marker of IR in young patients even with a normal BMI, mainly in an ignored site such as the knuckles. It has potential value as a useful tool for screening patients with a high-metabolic risk in early stages of the disease \[[@CR6]\]. Patients with PCOS have a higher risk for developing gestational diabetes (OR = 2.1) and T2DM (OR = 8.8) and a higher prevalence of T2DM. Furthermore, when added to AN, the prevalence of T2DM increases \[[@CR7], [@CR8]\]. Early androgenetic alopecia has been suggested as a clinical marker of IR, as well as presenting an increased CVD risk \[[@CR9]\]. NAFLD has been associated with IR and is an early detectable marker of metabolic disease. It is found most frequently in women with gestational diabetes mellitus. Patients with NAFLD present a three- to fourfold increased risk of developing T2DM \[[@CR10]\].

Act Earlier---Insulin Resistance Clinical Syndrome {#Sec4}
==================================================

We recommend a T2DM approach not centered on hyperglycemia but on strict management of well-accepted IR clinical expressions. Furthermore, we could go a step further and develop an easy and clear name to identify clinical expressions of IR, such as IR clinical syndrome. Therapy should be as strict as proposed today once postprandial or fasting hyperglycemia occurs. Under this perspective, the main disorder to start therapy must be IR clinical expressions (e.g., AN, androgenic alopecia, PCOS). As soon as they appear, instead of delaying therapy until the diagnosis of T2DM, obesity, hypertension, dyslipidemia, or CVD, all these individuals should undergo an intensive aerobic and anaerobic exercise program, a weight control low-calorie diet, and likely for some metformin therapy (i.e., high-risk patients with other comorbidities) under close surveillance.

Treating only an elevated IR laboratory index could be imprecise and lead to the other side of the spectrum, treating surrogate markers rather than patients, a common practice nowadays that diminishes resources and diverts attention from those who could really benefit the most. However, when several IR clinical manifestations are taken into account, it is difficult to ignore that these are patients who will develop obesity, metabolic syndrome, T2DM, and CVD in the medium term. Our lack of a strong action in this scenario is unreasonable and enhances epidemic growth.

Conclusion {#Sec5}
==========

The game is set, the stakes are high, and the call for action is clear. On a global scale, direct investment in diabetes prevention may reduce the economic burden of the disease. In day-to-day clinical practice, augmenting quality of life and life expectancy should be the main goals for young patients with a high metabolic risk. Therefore, when facing a patient with early clinical signs of IR, it is our responsibility to strongly and closely intervene as soon as possible.
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